Lumexa Imaging (NASDAQ:LMRI) Releases FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.710-0.770 for the period, compared to the consensus estimate of 0.620. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Stock Up 0.6%

Shares of NASDAQ LMRI opened at $11.73 on Thursday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.40 and a current ratio of 1.40. Lumexa Imaging has a 52 week low of $6.45 and a 52 week high of $19.45. The stock has a market capitalization of $1.13 billion and a P/E ratio of -19.88. The stock’s fifty day moving average is $10.70 and its 200 day moving average is $10.92.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LMRI shares. Weiss Ratings upgraded shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research report on Thursday, June 25th. Wall Street Zen cut Lumexa Imaging from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Barclays decreased their price target on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Insiders Place Their Bets

In related news, Director Brett Brodnax bought 35,000 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the completion of the transaction, the director directly owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This represents a 129.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LMRI. Barclays PLC acquired a new stake in Lumexa Imaging during the 4th quarter worth approximately $133,000. Sandia Investment Management LP acquired a new position in Lumexa Imaging in the 4th quarter valued at approximately $185,000. Hudson Bay Capital Management LP bought a new position in shares of Lumexa Imaging during the fourth quarter valued at $237,000. Oxford Asset Management LLP acquired a new position in shares of Lumexa Imaging during the fourth quarter worth $670,000. Finally, Burkehill Global Management LP bought a new stake in shares of Lumexa Imaging in the fourth quarter worth $925,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).